We searched the Cochrane Library and PubMed for relevant randomised trials and other high-quality studies (eg, systematic reviews, meta-analyses) between Jan 1, 2000, and July 1, 2012, for the terms “HPV”, “human papillomavirus”, “HPV vaccination”, “cervical cancer”, “cervical carcinoma”, “cervical neoplasia”, and “cervical carcinogenesis”. Widely cited older publications that we judged to have remained important references were also included. References from relevant articles identified by our
SeminarHuman papillomavirus and cervical cancer
Introduction
One of the most important scientific discoveries of the past 30 years is the causal link between human papillomavirus infection of the cervix and cervical cancer. This finding resulted from the original seminal findings by Harald zur Hausen and his group, that human papillomavirus 16 can be detected in cervical cancer tissue, and was followed by an enormous worldwide effort involving epidemiologists, molecular biologists, vaccinologists, and clinicians culminating in the development of effective prophylactic vaccines for human papillomavirus, which have the means to prevent 70–80% of cervical cancer. zur Hausen was awarded the Nobel Prize in Physiology or Medicine in 2008, in recognition of his discovery.
Human papillomavirus belongs to the papillomavirus family of viruses, which have a diverse range of hosts in both animals and man. The family has an agreed taxonomy that is based on genome sequence homology, biological function, and pathological effect.1 More than 100 types of human papillomavirus have been identified, including 13 high-risk types, which are responsible for cervical neoplasias and other anogenital and oropharyngeal cancers.
We review the worldwide epidemiology and natural history of cervical human papillomavirus infection, the virus's lifecycle, and the process of viral oncogenesis. We then discuss how the unique relationship between human papillomavirus and cervical cancer has been exploited for primary (prophylactic vaccines) and secondary (screening) prevention.
Section snippets
Epidemiology
Human papillomavirus infection is the most common sexually transmitted infection worldwide and most sexually active individuals of both sexes will acquire it at some point during their life.2 On the basis of a meta-analysis3 of 1 million women with normal cervical cytology, around 291 million women worldwide are estimated to have human papillomavirus infection of the cervix at a given point, corresponding to an average prevalence of 10·4%, though prevalence is higher in women younger than 25
The viral lifecycle
Human papillomavirus infects only epithelial cells and depends on the differentiation pathway of epithelial cells to complete its lifecycle.26 Human papillomavirus infects cells in the basal layer of the epithelium, probably via microabrasions in the epithelial surface. It capitalises on the lateral extension of basal cells that accompanies wound healing to gain entry to the cell. Infectious internalisation takes several hours, after which viral DNA is released from the capsid and transported
Prophylactic vaccines
Understanding of the ubiquitous role of human papillomavirus infection in all CIN and cervical cancer combined with an understanding of human papillomavirus natural history has led to the development of the first prophylactic cancer vaccines. These vaccines contain human papillomavirus L1 self-assembling virus-like particles (figure 3), which induce strong neutralising antibody responses against human papillomavirus infection.60 These antibodies are thought to block the human papillomavirus
Human papillomavirus testing in cervical screening
Because of its crucial causal role and the need for continued expression to maintain the disease phenotype, human papillomavirus can be used as a biomarker of cervical cancer and precancer. Randomised trials88, 89, 90 have shown that human papillomavirus DNA testing provides greater sensitivity than does cytology for detection of CIN. Human papillomavirus testing is more reproducible with less subjective analytical characteristics,91 and users need less training and expertise. The major
The role of human papillomavirus testing
Atypical cytology of unknown significance or borderline cytology are associated with underlying CIN2 or worse in roughly 10% of cases. In atypical cytology of unknown significance or borderline cytology, about 60% test positive for high-risk human papillomavirus, which enables human papillomavirus testing to identify those at very low risk (human papillomavirus negative), who can be routinely recalled at standard screening intervals, whereas a human papillomavirus positive result warrants
Conclusion
Human papillomavirus is a well-established cancer-causing infectious agent that is almost exclusively sexually transmitted and has increased in prevalence in many parts of the world during the past few decades.10, 105 Only comprehensive cervical screening programmes have avoided a corresponding epidemic of cervical cancer.105 Thus, economic improvements in developing countries will not be sufficient to overcome the present international disparities in cervical cancer burden unless human
Search strategy and selection criteria
References (105)
- et al.
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Virology
(2010) - et al.
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis
Lancet Infect Dis
(2007) - et al.
The cervical cancer epidemic that screening has prevented in the UK
Lancet
(2004) - et al.
Human papillomavirus and cervical cancer
Lancet
(2007) - et al.
The carcinogenicity of human papillomavirus types reflects viral evolution
Virology
(2005) - et al.
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
Lancet Oncol
(2012) - et al.
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis
Lancet Oncol
(2012) Interaction of human papillomaviruses with the host immune system: a well evolved relationship
Virology
(2009)- et al.
Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis
J Biol Chem
(2000) - et al.
Clinician's guide to human papillomavirus immunology: knowns and unknowns
Lancet Infect Dis
(2009)
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7·3 years in young adult women
Vaccine
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
Lancet
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Lancet Oncol
Beyond cervical cancer: burden of other HPV-related cancers among men and women
J Adolesc Health
Adolescent and young adult HPV vaccination in Australia: achievements and challenges
Prev Med
Papillomavirus vaccines in perspective
Lancet
A multimeric L2 vaccine for prevention of animal papillomavirus infections
Virology
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
Virology
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
Gynecol Oncol
Development of therapeutic HPV vaccines
Lancet Oncol
Clinician's guide to human papillomavirus immunology: knowns and unknowns
Lancet Infect Dis
Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial
Lancet
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
Lancet Oncol
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
Lancet Oncol
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial
Eur J Cancer
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial
Lancet Oncol
Prevalence of HPV infection among females in the United States
JAMA
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide
Int J Cancer
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study
Cancer Epidemiol Biomarkers Prev
Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies
Int J Cancer
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. GLOBOCAN 2008
Human papillomavirus infection in a population-based sample of women in Algiers, Algeria
Int J Cancer
HPV infection in women with and without cervical cancer in Conakry, Guinea
Br J Cancer
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica
J Infect Dis
Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results
J Infect Dis
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
BMJ
Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology
Int J Cancer
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection
J Natl Cancer Inst
Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies
Lancet
Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23 017 women without carcinoma of the cervix from 23 epidemiological studies
Int J Cancer
Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer
Cancer Epidemiol Biomarkers Prev
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer
Int J Cancer
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
Int J Cancer
The papillomavirus life cycle
J Clin Virol
The natural history of cervical HPV infection: unresolved issues
Nat Rev Cancer
The biological properties of E6 and E7 oncoproteins from human papillomaviruses
Virus Genes
Pathology and epidemiology of HPV infection in females
Gynecol Oncol
The role of TP53 in cervical carcinogenesis
Hum Mutat
E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
Cancer Res
Cited by (821)
Cassia fistula L. bark fraction modulated GSK3β/ p53 expression for mitochondrial mediated apoptosis in HeLa cells
2024, South African Journal of BotanyGenetic and epigenetic alterations in DNA repair genes and treatment outcome of chemoradiotherapy in cervical cancer
2024, Critical Reviews in Oncology/HematologyA comparative study of treatment of cervical low-grade squamous intraepithelial lesions (LSIL)
2024, Photodiagnosis and Photodynamic TherapyMicroRNA involvement in cervical cancer chemotherapy drug resistance: Restoring sensitivity to chemotherapeutic drugs
2024, Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision SolutionsAtypical glandular cells in Pap tests: cytology-histology correlation and risk assessment with human papillopmavirus (HPV) testing
2024, Journal of the American Society of Cytopathology